The same patterns, prescriptions issued at scale, with limited assessment, often through telehealth platforms, often without meaningful follow-up, have continued to attract regulatory scrutiny across the country
So of course we had lots of questions, of course, like, so the POTS patients wanna know, is it okay in people with POTS and the EDS patients and the ME/CFS patients, everybody wants to know like, is it okay to, with their comorbid conditions
On October 8, 2025, the National Academy of Medicines Health in the Headlines series brought together experts who have studied, prescribed, and worked with patients taking these drugs to discuss what GLP-1s actually canand cantdo, how safe they are, if they are worth the cost, and what can be expected from these miracle drugs in the future
Goldman Sachs has projected a $100bn number for these drugs like its inevitable